News

DHS S&T Calls for Submissions to Biometric Tech Rally

The U.S. Department of Homeland Security (DHS) Science and Technology Directorate (S&T) invites biometric technology developers to apply to participate in the 2021 Biometric Technology Rally. Started in 2018, the Biometric Technology Rally challenges industry to deliver fast, accurate, and easy-to-use biometric recognition capabilities to improve security and user facilitation at checkpoint processing.

Building on the high throughput of biometric technology capabilities demonstrated by industry over the last three years, the 2021 Biometric Technology Rally will focus on evaluating the ability of systems to reliably collect and/or match images of individuals, including those wearing face masks. The intent is to improve the ability to recognize people without requiring travelers to remove protective equipment, reducing risk for both the public and frontline security checkpoint personnel.

The 2021 Biometric Technology Rally will be held at the Maryland Test Facility (MdTF) in Upper Marlboro, Maryland, later this fall. Testing will be performed in controlled scenarios relevant to DHS operations. Providers of face and multi-modal biometric acquisition systems, as well as providers of biometric matching algorithms, are encouraged to participate.

“In the past year, we have seen tremendous innovation from the biometrics industry to adapt to new challenges during the COVID-19 pandemic,” said Arun Vemury, director of S&T’s Biometric and Identity Technology Center. “We observed very strong performances from technology developers; especially in their ability to recognize individuals under previously challenging situations. Now it’s time to see if further innovation and improvement can be achieved to further reduce errors and provide more consistent and equitable performance under challenging conditions.”

Technology providers will have the opportunity to participate in a Stakeholder Demonstration Day to showcase their capabilities to government and private sector stakeholders. Past events included representatives from more than 30 organizations, including DHS, the Department of Defense, the Department of State, the Federal Bureau of Investigation, the National Institute of Standards and Technology, the General Services Administration, international government partners, the aviation industry, and other critical infrastructure stakeholders.

As in previous rallies, data collected during scenario testing will be used to assess the performance and robustness of matching algorithms. DHS will use the results of the 2021 Biometric Technology Rally to inform planning activities, provide feedback to industry participants to accelerate and improve product capabilities, and guide researchers to enable the development of next generation capabilities.

Applications are due no later than July 15, 2021. Please contact peoplescreening@hq.dhs.gov for more information about the upcoming events.

Recent News

06/29/2022

Bio-plastics startup wins Lighthouse Labs pitch contest

Charlottsville, VA (Virginia Business) – While pitching to the sharks, entrepreneur Alec Brewer told them, “I do have white powder in my pocket,” before quickly clarifying that it wasn’t an illicit substance: “It’s PHB! It’s PHB!” The co-founder and CEO of Charlottesville-based biodegradable plastics manufacturer Ourobio, Brewer explained that his company makes PHB, or polyhydroxybutyrate,

06/26/2022

USA FDA Grants Fast Track Designation to ReAlta Life Sciences’ Lead Compound RLS-0071

ReAlta Life Sciences (“ReAlta”), Inc., a clinical stage, rare disease company dedicated to harnessing the power of the immune system to address life threatening diseases, announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to RLS-0071 for the treatment of hypoxic ischemic encephalopathy (HIE). RLS-0071 is the Company’s lead dual

06/20/2022

Adial Pharmaceuticals Awarded Additional U.S. Patent Combining the Use of the Company’s Proprietary Genetic Diagnostic With AD04 to Treat Alcohol and Drug Dependence

New patent covers the use of the full genetic panel measuring all five genetic biomarkers CHARLOTTESVILLE, Va., — Adial Pharmaceuticals, Inc. (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, today announced patent number 11,351,154 was issued on June 7, 2022, by